Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ovid Therapeutics Inc. - Common Stock (NQ: OVID )

0.6438 -0.0019 (-0.29%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 280,652
Open 0.6500
Bid (Size) 0.6420 (4)
Ask (Size) 0.6800 (10)
Prev. Close 0.6457
Today's Range 0.6316 - 0.6596
52wk Range 0.5714 - 3.930
Shares Outstanding 70,417,345
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
From Ovid Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
-32.80%
-32.80%
1 Month
-11.81%
-11.81%
3 Month
-38.10%
-38.10%
6 Month
-43.53%
-43.53%
1 Year
-83.23%
-83.23%

More News

Read More
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Expert Outlook: Ovid Therapeutics Through The Eyes Of 7 Analysts
Via Benzinga
The Latest Analyst Ratings For Ovid Therapeutics
Via Benzinga
Evaluating Ovid Therapeutics: Insights From 6 Financial Analysts
Via Benzinga
Ovid Therapeutics to Host Investor Event
From Ovid Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin
From Ovid Therapeutics Inc.
Via GlobeNewswire
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at Upcoming September Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
OVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Ovid Therapeutics to Present at Upcoming August Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
From Ovid Therapeutics Inc.
Via GlobeNewswire
7 Sorry Biotech Stocks Set to Make Investors Sad
Via InvestorPlace
eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
From Ovid Therapeutics Inc.
Via GlobeNewswire
Nasdaq Surges Over 200 Points; Aaron's Shares Jump
Via Benzinga
Is the Stock Market Closed on Juneteenth 2024?
Via InvestorPlace
ACHR Stock Alert: Archer Aviation Strikes New Deal With Signature Aviation
Via InvestorPlace
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
AAN Stock Alert: The Aaron’s Company Pops 33% on Take-Private Deal
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.